Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Sonmez, Ozlem

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Coronaphobia: A barrier to ongoing cancer treatment?
    (WILEY, 2022-01-01) Sonmez, Ozlem; Tezcanli, Evrim; Tasci, Elif Senocak; Kazanci, Hande Busra; Altinok, Ayse; Toklucu, Elvan; Tasci, Yusuf; Aydogdu, Cise; Aydin, Aysegul Bakir; Yuce, Sabiha; Oyan, Basak
    Introduction Increased stress levels caused by the pandemic might cause delays in cancer treatment. We conducted a survey among cancer patients undergoing treatment to evaluate their psychological wellbeing and treatment adherence during Coronavirus disease 19 (COVID-19) pandemic. Material and Methods Patients receiving active chemotherapy at a private oncology center between January and May 2021 were included. Healthy volunteers were employees of a district health directorate with no history of cancer or chronic disease. Treatment adherence was described as compliant if the prescribed treatment was received within a week and the information was gained from patient charts. Hospital anxiety and depression scale (HADS) and COVID-19 phobia scale (CP19-S) were administered to participants. Results 402 participants were included
  • Thumbnail Image
    Item
    Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group
    (AVES, 2019-01-01) Aytac, Erman; Aslan, Fatih; Cicek, Bahattin; Erdamar, Sibel; Gurses, Bengi; Guven, Koray; Falay, Okan; Karahasanoglu, Tayfun; Selcukbiricik, Fatih; Selek, Ugur; Atalar, Banu; Balik, Emre; Tozun, Nurdan; Rozanes, Izzet; Arican, Ali; Hamzaoglu, Ismail; Baca, Bilgi; Mandell, Nil Molinas; Saruc, Murat; Goksel, Suha; Demir, Gokhan; Agaoglu, Fulya; Yakicier, Cengiz; Ozbek, Ugur; Ozben, Volkan; Ozyar, Enis; Guner, Ahmet Levent; Er, Ozlem; Kaban, Kerim; Bolukbasi, Yasemin; Bugra, Dursun; Ahishali, Emel; Asian, Fatih; Boz-bas, Aysun; Hamzaoglu, Hulya; Karaman, Ahmet; Kucukmetin, Nurten Turkel; Vardareli, Eser Kutsal; Onder, Fatih Oguz; Sisman, Gurhan; Tiftikci, Arzu; Unal, Hakan Umit; Yapali, Suna; Acar, Sami; Agcaoglu, Orhan; Aghayeva, Afag; Akyuz, Ali; Atasoy, Deniz; Batik, Emre; Bayraktar, Ilknur Erenler; Bayram, Onur; Bilgic, Cagri; Bilgin, Ismail Ahmet; Can, Ugur; Dulgeroglu, Onur; Durukan, Ugur; Gencosmanoglu, Rasim; Gonenc, Murat; Gurbuz, Bulent; Kaya, Mesut; Omarov, Nail; Ozben, Volkan; Ozgur, Ilker; Ozoran, Emre; Sobutay, Erman; Uras, Cihan; Uymaz, Derya; Zenger, Serkan; Ozbek, Ugur; Yakicier, M. Cengiz; Afsar, Cigdem Usul; Bozkurt, Mustafa; Demir, Atakan; Er, Ozlem; Kanitez, Metin; Korkmaz, Taner; Mandel, Nil Molina; Mert, Askhan Guven; Ozer, Leyla; Sonmez, Ozlem; Tunali, Didem; Uluc, Basak Oyan; Yazar, Aziz; Yildiz, Ibrahim; Demirkurek, Cengiz; Guner, Ahmet Levent; Vardareli, Erkan; Armutlu, Aye; Baba, Fisun; Ersozlu, Ilker; Kapran, Yersu; Sahin, Davut; Abacioglu, Mehmet Ufuk; Bese, Nuran; Durankus, Nilufer Kilic; Gural, Zeynep; Ozyar, Enis; Sengoz, Meric; Sezen, Duygu; Caliskan, Can; Guven, Koray; Karaaslan, Ercan; Kizilkaya, Esref; Suleyman, Erdogan; Grp, Istanbul
    The geographical location and differences in tumor biology significantly change the management of gastric cancer. The prevalence of gastric cancer ranks fifth and sixth among men and women, respectively, in Turkey. The international guidelines from the Eastern and Western countries fail to manage a considerable amount of inconclusive issues in the management of gastric cancer. The uncertainties lead to significant heterogeneities in clinical practice, lack of homogeneous data collection, and subsequently, diverse outcomes. The physicians who are professionally involved in the management of gastric cancer at two institutions in Istanbul, Turkey, organized a consensus meeting to address current problems and plan feasible, logical, measurable, and collective solutions in their clinical practice for this challenging disease. The evidence-based data and current guidelines were reviewed. The gray zones in the management of gastric cancer were determined in the first session of this consensus meeting. The second session was constructed to discuss, vote, and ratify the ultimate decisions. The identification of the T stage, the esophagogastric area, imaging algorithm for proper staging and follow-up, timing and patient selection for neoadjuvant treatment, and management of advanced and metastatic disease have been accepted as the major issues in the management of gastric cancer. The recommendations are presented with the percentage of supporting votes in the results section with related data.
  • Thumbnail Image
    Item
    Concurrent Use of Cyclin Dependent Kinase 4/6 (CDK4/6) Inhibitors with Palliative Radiotherapy for Metastatic Breast Cancer Patients: A Review of Toxicity
    (KARE PUBL, 2021-01-01) Sonmez, Ozlem; Tezcanli, Evrim
    Breast cancer remains to be the most common cancer in women. Given the recent developments in oncology, while more women with early breast cancer are being cured, patients with metastatic breast cancer are living longer. There have been improvements in the treatment of hormone-sensitive metastatic breast cancer by the addition of CDK 4/6 inhibitors to endocrine treatment. CDK 4 and CDK 6 control entry into the cell cycle via estrogen signaling pathway and their inhibition was shown to prevent tumor cell cycle progression. Three CDK4/6 inhibitors available for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer are palbociclib, ribociclib, and abemaciclib. CDK 4/6 inhibitors are suggested as radiosensitizers given their mechanism of action that inhibits cell cycle progression as well as DNA repair. However, there are concerns regarding their concurrent use with radiotherapy given their potential to delay normal tissue repair. Currently, there are several retrospective series suggesting a site-dependent toxicity. After reviewing preclinical and retrospective studies, we suggest further studies are required to clarify the safety of this combination. Until then, oncologists should evaluate each case with caution regarding the potential risks of CDK 4/6 inhibitors in combination with radiotherapy.
  • Thumbnail Image
    Item
    The Importance of Nutrition Therapy as a Contributor to the Success of Cancer Treatment
    (KARE PUBL, 2020-01-01) Sonmez, Ozlem
    Cancer is a leading cause of morbidity and mortality in the world. Although developments in early cancer detection and treatments led to improved survival, malnutrition remains to be a significant problem that may affect the response to treatments. Cancer patients remain to be at high risk for malnutrition secondary to local and systemic/metabolic effects of tumors and cancer treatments. The mechanism of cancer cachexia is multifactorial and includes inadequate nutritional intake and systemic inflammation that leads to a metabolic imbalance. Weight loss and cachexia are of prognostic significance and are closely linked to the quality of life. Since early detection and intervention lead to improved outcomes, screening and monitoring nutritional status are critical components of cancer care leading to adequate nutritional therapies. This review article aims to provide an overview of the mechanisms of malnutrition and cancer related cachexia and recent guidelines with the current evidence on the importance of nutrition therapy for cancer patients.